<DOC>
	<DOCNO>NCT00002840</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell , may effective treatment anaplastic oligodendroglioma . Combining combination chemotherapy radiation therapy may kill tumor cell . PURPOSE : Randomized phase III trial compare radiation therapy without combination chemotherapy patient resect anaplastic oligodendroglioma .</brief_summary>
	<brief_title>Radiation Therapy With Without Combination Chemotherapy Patients With Resected Anaplastic Oligodendroglioma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival time first progression patient anaplastic oligodendroglioma treat radiotherapy without adjuvant procarbazine , lomustine , vincristine ( PCV ) follow surgical resection . II . Investigate effect PCV quality life neurologic function patient . III . Determine toxicity PCV patient . IV . Correlate chromosomal lesion ( 1p and/or 19q , 9p , p53 loss mutation , amplification chromosome 7 , loss chromosome 10 ) progression-free overall survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord age , extent resection , performance status , prior surgery , participate center . Patients randomize one two treatment arm . Arm I : Within 4-6 week surgery , patient undergo radiotherapy 7 week residual tumor volume . Arm II : Patients undergo radiotherapy arm I , begin chemotherapy within 4 week completion radiotherapy . Patients receive oral lomustine day 1 , oral procarbazine day 8-21 , vincristine IV day 8 29 . Treatment repeat every 6 week stable respond patient total 6 course . Patients disease recurrence may receive 6 additional course chemotherapy another modality investigator 's discretion . Patients follow every 3 month 1 year every 6 month survival . PROJECTED ACCRUAL : A total 350 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose oligodendroglioma oligoastrocytoma ( least 25 % oligodendral element ) Lowgrade oligodendroastrocytoma oligodendroglioma recurrent surgery without radiotherapy allow Prior partial gross total resection tumor ( biopsy case surgical option ) require At least 3 follow histologic anaplastic feature : High cellularity Endothelial abnormality Nuclear abnormality Necrosis Mitoses PATIENT CHARACTERISTICS : Age : 16 69 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.4 mg/dL Renal : Creatinine great 1.3 mg/dL Creatinine clearance least 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception No active uncontrolled infection No disease , include malignancy , would preclude study No neurologic psychiatric disturbance would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy skull Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>